Evidence-Based Strategies to Minimize the Likelihood of Axillary Lymph Node Dissection in Clinically Node-Positive Patients Following Neoadjuvant Chemotherapy

[1]  T. Kühn,et al.  Abstract GS4-02: Oncological Outcomes Following Omission of Axillary Lymph Node Dissection in Node Positive Patients Downstaging To Node Negative with Neoadjuvant Chemotherapy: the OPBC-04/EUBREAST-06/OMA study , 2023, Cancer Research.

[2]  D. van Klaveren,et al.  Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer. , 2022, JAMA surgery.

[3]  G. Plitas,et al.  Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event. , 2021, JAMA oncology.

[4]  J. Heil,et al.  A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients , 2020, Annals of surgery.

[5]  P. Fasching,et al.  Pembrolizumab for Early Triple-Negative Breast Cancer. , 2020, The New England journal of medicine.

[6]  J. Bellon,et al.  Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer , 2019, Annals of Surgical Oncology.

[7]  Bernard T. Lee,et al.  Lymphedema Incidence After Axillary Lymph Node Dissection: Quantifying the Impact of Radiation and the Lymphatic Microsurgical Preventive Healing Approach , 2019, Annals of plastic surgery.

[8]  M. Morrow,et al.  Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection? , 2018, Annals of Surgical Oncology.

[9]  A. Taghian,et al.  Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments. , 2018, Gland surgery.

[10]  A. Giuliano,et al.  Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial , 2017, JAMA.

[11]  J. Boughey,et al.  Breast Cancer-Related Lymphedema Risk is Related to Multidisciplinary Treatment and Not Surgery Alone: Results from a Large Cohort Study , 2017, Annals of Surgical Oncology.

[12]  H. Kuerer,et al.  Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members , 2017, Annals of Surgical Oncology.

[13]  Jeannette Y Lee,et al.  Does Axillary Reverse Mapping Prevent Lymphedema After Lymphadenectomy? , 2017, Annals of surgery.

[14]  H. Kuerer,et al.  Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  K. Hunt,et al.  Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0–T4, N1–N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance) , 2016, Annals of surgery.

[16]  H. Kuerer,et al.  Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). , 2015, Annals of surgery.

[17]  H. Kuerer,et al.  Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial. , 2015, JAMA surgery.

[18]  E. Rutgers,et al.  Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. , 2015, Annals of surgery.

[19]  M. Brackstone,et al.  Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Mclaughlin,et al.  Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. , 2013, JAMA.

[21]  A. Schneeweiss,et al.  Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  T. Fehm,et al.  Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. , 2013, The Lancet. Oncology.

[23]  A. Luini,et al.  Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. , 2013, The Lancet. Oncology.

[24]  H. Kuerer,et al.  Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2‐positive breast cancer , 2010, Cancer.

[25]  E. Rutgers,et al.  UvA-DARE ( Digital Academic Repository ) Sentinel Node Identification Rate and Nodal Involvement in the EORTC 10981-22023 AMAROS , 2010 .

[26]  M. Ross,et al.  Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy is Accurate and Reduces the Need for Axillary Dissection in Breast Cancer Patients , 2009, Annals of surgery.

[27]  C. Sagan,et al.  Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Todd M Tuttle,et al.  Factors predicting failure to identify a sentinel lymph node in breast cancer. , 2005, Surgery.

[29]  Terry L. Smith,et al.  Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  G. Hortobagyi,et al.  Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. , 1999, Annals of surgery.

[31]  Safely Avoiding Axillary Lymphadenectomy after Neoadjuvant Chemotherapy for Patients with Proven Axillary Lymph Node Involvement Early Breast Cancer? The French Multicenter Prospective Ongoing GANEA 3 Study , 2020 .

[32]  Giulia Bianchi,et al.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.